Announcement PDF Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com ASX ANNOUNCEMENT 13 November 2025 Results of Annual General Meeting Melbourne, Australia; 13 November 2025: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), advises that its Annual General Meeting of Shareholders was held today at the Australian Institute of Company Directors, Level 26, 367 Collins Street, Melbourne, VIC 3000 at 10.00 am AEDT. The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange. Resolutions 1 to 6 were carried on a poll, with Resolution 4 (Approval of 10% Placement Facility) being carried by a sufficient majority as a special resolution. Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached. -ENDS- Authorised for release by Dr Kilian Kelly, CEO & Managing Director CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com Lauren Nowak, Media Contact, +61 (0)400 434 299, investors@cynata.com About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods. Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome. Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. Disclosure of Proxy Votes Cynata Therapeutics Limited Annual General Meeting Thursday, 13 November 2025 In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting. Automic GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au ABN 27 152 260 814 Proxy Votes Poll Results (if applicable) Results Resolution Decided by Show of Hands (S) or Poll (P) Total Number of Proxy Votes exercisable by proxies validly appointed FOR AGAINST ABSTAIN PROXY'S DISCRETION FOR AGAINST ABSTAIN OUTCOME 1 Adoption of Remuneration Report P 81,531,558 80,627,408 98.89% 370,162 0.45% 186,898 533,988 0.65% 84,527,786 99.56% 370,162 0.44% 186,898 - 2 Re-election of Dr Geoff Brooke as a Director P 82,381,337 81,580,953 99.03% 312,061 0.38% 250,826 488,323 0.59% 85,691,220 99.64% 312,061 0.36% 250,826 Carried 3 Re-election of Ms Janine Rolfe as a Director P 82,381,337 81,000,868 98.32% 907,894 1.10% 250,826 472,575 0.57% 85,095,387 98.94% 907,894 1.06% 250,826 Carried 4 Approval of 10% Placement Facility P 82,630,426 80,441,267 97.35% 405,795 0.49% 1,737 1,783,364 2.16% 85,846,575 99.53% 405,795 0.47% 1,737 Carried 5 Ratification of the issue of the Corporate Adviser Options P 82,549,600 80,341,884 97.33% 527,735 0.64% 82,563 1,679,981 2.04% 85,643,809 99.39% 527,735 0.61% 82,563 Carried 6 Ratification of the issue of the Acuity Capital Collateral Shares P 82,588,426 78,774,849 95.38% 2,111,039 2.56% 43,737 1,702,538 2.06% 84,099,331 97.55% 2,111,039 2.45% 43,737 Carried